Compare Enveric Biosciences Inc (ENVB) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Oracle Corporation — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Oracle Corporation trades at $141.56 (market cap $411.34B). The key difference: Oracle Corporation is far larger — about 60491.2× Enveric Biosciences Inc's market cap, and Oracle Corporation pays a 1.47% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Oracle Corporation for 72 Days on average.
| ENVB | ORCL | |
|---|---|---|
Market Cap | $6.80M | $411.34B |
Volume | 64,867 | 41,276,815 |
Sector | Health | Technology |
52-Week High | $10.80 | $313.00 |
52-Week Low | $1.27 | $114.99 |
Typical Hold Time | 14 Days | 72 Days |
Enterprise Value | -$1.49M | $535.15B |
Dividend Yield | — | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Oracle (ORCL) trades at $143.56, down 0.83% amid a bearish technical signal, though recent earnings consistently beat expectations with Q2 2026 EPS of $1.92 versus $1.74 expected. The company shows strong fundamentals with 2025 revenue of $57.40B and net income margin of 26.36%, while analyst consensus remains bullish with a $236.52 price target. News highlights AI cloud growth of 120% in Q1 2026 but also layoffs and market concerns over AI spending cycles.
The outlook is mixed: robust AI-driven revenue growth and high profitability support upside, but technical weakness and macroeconomic risks like Fed policy pose near-term headwinds. Investors face opportunity from AI demand against volatility from high debt and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
